Hepatitis E Vaccines MarketSize, Share & Industry Analysis, 2026-2034By Vaccine Type / Platform TechnologyBy Development & Regulatory StageBy Genotype Coverage / Antigen TargetBy Dosing RegimenBy Target Population / Risk GroupBy Application / Use SettingBy Distribution / Procurement ChannelBy Adjuvant SystemBy End UserBy Route of Administration
Full title & scope — all 10 axes with their segments
Hepatitis E Vaccines Market Size, Share & Industry Analysis, By Vaccine Type / Platform Technology (Recombinant Protein / Virus-Like Particle (VLP) Vaccines, DNA-Based Vaccine Candidates, mRNA-Based Vaccine Candidates, Live-Attenuated Vaccine Candidates, Inactivated Whole-Virus Vaccine Candidates), By Development & Regulatory Stage (Licensed / Commercially Marketed, Phase III Clinical Trials, Phase II Clinical Trials, Phase I Clinical Trials, Preclinical Research Stage), By Genotype Coverage / Antigen Target (Genotype 1-Derived Antigen Candidates, Genotype 2-Relevant Candidates, Genotype 3-Relevant Candidates, Genotype 4-Relevant Candidates, Pan-Genotype (Cross-Protective) Candidates), By Dosing Regimen (Two-Dose Regimen, Three-Dose Regimen, Single-Dose Candidates), By Target Population / Risk Group (Women of Reproductive Age, Including Pregnant Women, Children and Adolescents, General Adult Population in Endemic Areas, Travelers to Endemic Regions, Immunocompromised and Chronic Liver Disease Patients, Military and Occupational-Risk Personnel), By Application / Use Setting (Routine National Immunization Programs, Outbreak and Emergency Response Campaigns, Travel Medicine / Pre-Travel Vaccination, Occupational and Institutional Vaccination, Clinical Research and Trial Use), By Distribution / Procurement Channel (Government and National Immunization Programs, International and Multilateral Procurement, Private Hospitals and Clinics, Travel Medicine and Specialty Vaccination Clinics, Humanitarian and NGO-Led Outbreak Response Procurement), By Adjuvant System (Aluminum Hydroxide (Alum)-Adjuvanted, Non-Adjuvanted / Antigen-Only Formulations, Novel / Next-Generation Adjuvant Systems), By End User (Hospitals and Clinics, Government and Public Health Immunization Bodies, Travel Medicine and Occupational Health Clinics, Humanitarian and Outbreak-Response Organizations, Academic and Research Institutes), By Route of Administration (Intramuscular Injection, Investigational Needle-Free / Alternative Delivery Candidates), and Regional Forecast, 2026-2034
Segment definitions and share of revenue by product, animal, end user and region.
Segmentation Analysis
10 axesBy Vaccine Type / Platform Technology
5- 01Recombinant Protein / Virus-Like Particle (VLP) Vaccines
- 02DNA-Based Vaccine Candidates
- 03mRNA-Based Vaccine Candidates
- 04Live-Attenuated Vaccine Candidates
- 05Inactivated Whole-Virus Vaccine Candidates
By Development & Regulatory Stage
5- 01Licensed / Commercially Marketed
- 02Phase III Clinical Trials
- 03Phase II Clinical Trials
- 04Phase I Clinical Trials
- 05Preclinical Research Stage
By Genotype Coverage / Antigen Target
5- 01Genotype 1-Derived Antigen Candidates
- 02Genotype 2-Relevant Candidates
- 03Genotype 3-Relevant Candidates
- 04Genotype 4-Relevant Candidates
- 05Pan-Genotype (Cross-Protective) Candidates
By Dosing Regimen
3- 01Two-Dose Regimen (0, 1 Month)
- 02Three-Dose Regimen (0, 1, 6 Months)
- 03Single-Dose Candidates (Investigational)
By Target Population / Risk Group
7- 01Women of Reproductive Age
- 02Including Pregnant Women
- 03Children and Adolescents
- 04General Adult Population in Endemic Areas
- 05Travelers to Endemic Regions
- 06Immunocompromised and Chronic Liver Disease Patients
- 07Military and Occupational-Risk Personnel
By Application / Use Setting
5- 01Routine National Immunization Programs
- 02Outbreak and Emergency Response Campaigns
- 03Travel Medicine / Pre-Travel Vaccination
- 04Occupational and Institutional Vaccination (Military, Healthcare Workers)
- 05Clinical Research and Trial Use
By Distribution / Procurement Channel
5- 01Government and National Immunization Programs
- 02International and Multilateral Procurement (Gavi-Supported Stockpile, UNICEF Supply Division, ICG-Coordinated Emergency Stockpile)
- 03Private Hospitals and Clinics
- 04Travel Medicine and Specialty Vaccination Clinics
- 05Humanitarian and NGO-Led Outbreak Response Procurement
By Adjuvant System
3- 01Aluminum Hydroxide (Alum)-Adjuvanted
- 02Non-Adjuvanted / Antigen-Only Formulations
- 03Novel / Next-Generation Adjuvant Systems (Investigational)
By End User
5- 01Hospitals and Clinics
- 02Government and Public Health Immunization Bodies
- 03Travel Medicine and Occupational Health Clinics
- 04Humanitarian and Outbreak-Response Organizations
- 05Academic and Research Institutes
By Route of Administration
2- 01Intramuscular Injection (Standard)
- 02Investigational Needle-Free / Alternative Delivery Candidates
Segment categories shown for scope reference. See the Summary tab for revenue share by Vaccine Type / Platform Technology. Full segment-by-segment detail across every axis is available in the sample and full report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Hepatitis E Vaccines Market projected to reach?
USD 247.5 USD Million by 2034, CAGR 20.62%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
Asia Pacific leads with 78% of global revenue through 2034.
05Which segment leads the market?
Recombinant Protein / Virus-Like Particle (VLP) Vaccines is the largest line by Vaccine Type / Platform Technology, at 90.5% of revenue in 2025.
06Who are the key companies profiled?
Xiamen Innovax Biotech Co., Ltd., Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Zydus Lifesciences Ltd., Changchun Institute of Biological Products Co., Ltd., China National Biotec Group Co., Ltd. (Sinopharm), GSK plc, Serum Institute of India Pvt. Ltd., Bharat Biotech International Ltd., Biological E. Limited, Panacea Biotec Ltd., Indian Immunologicals Ltd., PT Bio Farma (Persero), Company for Vaccine and Biological Production No.1 (VABIOTECH), Walvax Biotechnology Co., Ltd., Chengdu Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., National Vaccine and Serum Institute (Egypt), Institut Pasteur de Dakar, The Biovac Institute, Croda International plc, InvivoGen. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.